PMID- 29390450
OWN - NLM
STAT- MEDLINE
DCOM- 20180220
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 51
DP  - 2017 Dec
TI  - Effect of probiotics on lipid profiles and blood pressure in patients with type 2 
      diabetes: A meta-analysis of RCTs.
PG  - e9166
LID - 10.1097/MD.0000000000009166 [doi]
LID - e9166
AB  - BACKGROUND: This meta-analysis aimed to systematically evaluate the effects of 
      probiotics on blood lipid and blood pressure among patients with type 2 diabetes 
      mellitus (T2DM) based on the randomized controlled studies. METHODS: PubMed, 
      Cochrane, Embase, Wanfang, China National Knowledge Infrastructure, and VIP 
      database were searched by the index words to identify the qualified randomized 
      control trial. The latest research was done in the January 2017. Mean difference 
      (MD) along with 95% confidence interval (CI) was used to analyze the included 
      outcomes. RESULTS: Ten trials were included at last with 297 patients in the 
      treatment group and 294 patients in the control group. Probiotics significantly 
      decreased the value of total cholesterol (SMD -0.57, 95% CI -0.92 to 0.21), 
      triglyceride (SMD -0.66, 95% CI -0.93 to 0.39), low-density lipoprotein (SMD 
      -0.40, 95% CI -0.79 to 0.01), systolic blood pressure (WMD -5.04, 95% CI -8.8 to 
      1.20), diastolic blood pressure (SMD -0.39, 95% CI -0.62 to 0.17), fasting blood 
      glucose (FBG) (SMD 3.54, 95% CI 1.94-5.15) compared with the placebo treatment. 
      Apart from this, probiotics could significantly improve the value of high-density 
      lipoprotein (SMD 0.38, 95% CI 0.03-0.73). CONCLUSION: Probiotics may decrease the 
      indexes of lipid profile, blood pressure, and FBG in patients with T2DM; 
      application of probiotics might be a new method for lipid profiles and blood 
      pressure management in T2DM.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights 
      reserved.
FAU - He, Jun
AU  - He J
AD  - Department of Endocrinology, The Third People's Hospital of Changzhou, Changzhou, 
      China.
FAU - Zhang, Fan
AU  - Zhang F
FAU - Han, Yan
AU  - Han Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Lipids)
SB  - IM
MH  - Blood Glucose/analysis
MH  - Blood Pressure/*drug effects
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Humans
MH  - Lipids/*blood
MH  - Probiotics/*therapeutic use
MH  - Randomized Controlled Trials as Topic
PMC - PMC5758152
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/02/03 06:00
MHDA- 2018/02/21 06:00
PMCR- 2017/12/22
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/21 06:00 [medline]
PHST- 2017/12/22 00:00 [pmc-release]
AID - 00005792-201712220-00037 [pii]
AID - MD-D-17-05099 [pii]
AID - 10.1097/MD.0000000000009166 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(51):e9166. doi: 10.1097/MD.0000000000009166.